Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.74 USD
Change Today -0.85 / -4.13%
Volume 287.7K
FLDM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Open
$20.58
Previous Close
$20.59
Day High
$20.63
Day Low
$19.70
52 Week High
03/20/15 - $46.38
52 Week Low
07/30/15 - $19.70
Market Cap
569.8M
Average Volume 10 Days
222.3K
EPS TTM
$-1.99
Shares Outstanding
28.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. It provides various preparatory instruments, including C1 single-cell auto prep system, a sample preparation system that isolates, processes, and profiles individual cells for genomic analysis; and access array systems that enables automated polymerase chain reaction (PCR)-based target enrichment, barcoding, and tagging of resequencing libraries and facilitates parallel amplification. The company also offers analytical instruments comprising Biomark HD system, a PCR analytical instrument for gene expression analysis, single-cell targeted gene expression analysis, microRNA analysis, single nucleotide polymorphism (SNP) genotyping, and digital PCR; EP1 system that performs high-throughput SNP genotyping and end-point digital PCR; and CyTOF 2 system, a mass cytometry instrument that performs single-cell protein analysis by analyzing cells labeled with a panel of reagents conjugated to stable metal isotopes. In addition, it provides integrated fluidic circuits (IFCs), such as C1, access array, dynamic array, digital array, and flex six IFCs; assays and reagents consisting of Delta Gene and SNP type assays, access array target-specific primers, and Maxpar Reagents. Further, the company’s products include juno systems and IFCs, callisto systems and IFCs, polaris systems and IFCs, and C1 mRNA Sequencing IFCs. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies. The company distributes its products through direct sales force and support organizations, distributors, or sales agents. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

474 Employees
Last Reported Date: 02/26/15
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: $490.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $320.0K
Chief Operating Officer
Total Annual Compensation: $325.0K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $325.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

fluidigm corp (FLDM) Key Developments

Fluidigm and OpGen Enter into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment

Fluidigm Corporation and OpGen, Inc. announced an expanded relationship and new agreement that includes collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of multi-drug resistance organism (MDRO) genes of pathogens, such as bacteria, fungi and viruses. The agreement establishes a framework for Fluidigm and OpGen to develop MDRO tests utilizing Fluidigm components and instruments, initially based on Fluidigm's Juno instrument for automating SNP genotyping assays and Fluidigm's Biomark system for endpoint and real-time PCR detection. Fluidigm and OpGen plan to cooperate on quality, regulatory and compliance as needed. The initial term of the agreement is for five years with the potential to extend for an additional five-year term.

Fluidigm Introduces Advanced Mass Cytometry System Along with Sample Barcoding for Markedly Improved Discovery Workflows

Fluidigm Corporation introduced Helios(TM), a CyTOF® platform that enables system-level biology at single-cell resolution, on an accessible, expandable system designed for breakthrough discovery. Mass cytometry has catalyzed the revolution of single-cell proteomics, enabling the most comprehensive understanding of cell phenotypes, signaling pathways and function. Helios dawns as the most advanced tool for cellular exploration with streamlined workflows and multi-modal capabilities for advancing single-cell biology. The Helios platform delivers an extensive list of features and advances to the core CyTOF technology, all intended to bring enhanced performance and convenience of operation. This includes a significantly more intuitive and easy-to-use software interface with real-time data display, normalization and control. Helios also provides improved sensitivity to detect and resolve lower abundance targets and an expanded mass range of 135 discrete channels with virtually no signal overlap or background noise compared to conventional techniques. This enables more comprehensive and straightforward panel designs and higher quality data sets. A synchronized suite of upgrades to the sample introduction assembly and procedure triples the rate of data acquisition, or system throughput, with a considerable increase in cell transmission efficiency and consistency. Fluidigm also announced proteomics sample barcoding, which enables Helios and all other CyTOF customers to take advantage of multiplexing in their experimental design. Fluidigm’s new barcoding reagent kit accommodates the unique barcoding of up to 20 samples such that they can be combined, stained and acquired as one multiplexed sample. Multiplexing improves data quality as samples are prepared, processed and acquired under a common protocol, thereby eliminating any technical variation from sample preparation through data collection. It substantially increases throughput by reducing staining protocol and instrument collection time. Barcoding is indispensable for any experiment where unraveling of biological complexity requires multiple samples, time points and assay conditions. Fluidigm will begin shipments of Helios systems in the third quarter of 2015. Fluidigm is unveiling the Helios platform with sample barcoding at CYTO 2015, the 30th Congress of the International Society for Advancement of Cytometry being held this week in Glasgow, United Kingdom with product demonstrations, seminars and workflow consultations available to all attendees. In addition, Fluidigm will be hosting a CyTOF User Group meeting and reception that will feature presentations by Fluidigm customers from around the world.

Fluidigm Corporation Announces its Callisto(TM) System

Fluidigm Corporation announced its Callisto(TM) system, a fully automated and programmable microfluidic cell culture system that integrates multifactorial dosing in 32 individual chambers for simultaneous cell culture. This innovative new platform will revolutionize the way cell biologists develop in vitro cell models. By providing multifactorial dosing, transfection, and precise environmental control of cells in a microfluidic environment, Callistois the first platform to enable stem cell and other cell researchers to design, optimize, and execute complex cell culture protocols, such as cellular reprogramming, differentiation, characterization, and dose response studies. With just a few touches on a computer screen, biologists will be able to study and analyze the developmental stages and behavior of living cells, such as induced pluripotent stem cells (iPScells), embryonic stem cells, and other cell types, in their microenvironment over the course of several weeks. The Callisto system consists of an automated instrument, specialized integrated fluidic circuit, reagent kit, and software suite. With minimal intervention, the platform enables scientists to easily and precisely manipulate the biological pathways that regulate cellular activity and fate decisions while monitoring their viability and phenotypic effects over the course of each study. More importantly, by running automated scripts in a nanoliter scale reaction size, each experiment can be executed with higher efficiency and drastically reduced labor and heterogeneity compared to manual, plate-based studies. Callisto is currently available for pre-order and is expected to begin shipping in the second half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $19.74 USD -0.85

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $22.30 USD -7.00
Luminex Corp $17.05 USD -0.14
NanoString Technologies Inc $15.18 USD +0.18
Natera Inc $18.13 USD -0.08
Pacific Biosciences of California Inc $5.54 USD +0.12
View Industry Companies
 

Industry Analysis

FLDM

Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit www.fluidigm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.